Trial Profile

A Phase 2 Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Advanced Unresectable or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erfonrilimab (Primary) ; Cisplatin; Paclitaxel
Indications Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use
Sponsors Jiangsu Alphamab Biopharmaceuticals

Most Recent Events

04 Aug 2022 Status changed from recruiting to completed.
08 Jun 2021 Results evaluating as of December 14, 2020, 15 pts presented at the 57th Annual Meeting of the American Society of Clinical Oncology
09 Jul 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Dec 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com